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The synthesis and the study of the antitumor activity  
of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]- 
thiadiazine hydrobromides
Aim. To synthesize and study the antitumor activity of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b]- 
[1,3,4]thiadiazine derivatives.
Results and discussion. To determine the antitumor activity of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]- 
triazolo[3,4-b][1,3,4]thiadiazine hydrobromides, the in vitro study was conducted on 60 lines of cancer cells (leu-
kemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate 
cancer and breast cancer) according to the standard procedure of the mitotic activity assessment of new poten-
tial bioactive compounds by the fluorescent coloring method (sulforhodamine B as a dye). It was performed in 
the US National Сancer Institute within the Development Therapeutic Program. It has been found that derivatives 
of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine exhibit the antineoplastic activity against a wide 
range of cancer cells lines and are promising core structures for creating new effective anticancer agents.
Experimental part. 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides were 
synthesized by the interaction of 4-amino-5-R-4H-1,2,4-triazole-3-thiols with 4-methoxyphenacyl bromide in 
ethyl acetate. The 1Н NMR spectra were recorded on a Bruker VXR-300 spectrometer (Germany) with the work-
ing frequency of 299.945 MHz.
Conclusions. A series of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides 
has been synthesized. The anticancer activity of the compounds obtained has been studied in the National 
Cancer Institute on 60 lines of tumor cells. Compounds that exhibit high levels of the antitumor activity have 
been found. It has been shown that the replacement of 3-H in compound 3a with ethyl or pentyl radicals leads to in-
crease in the antitumor activity against MDA-MB-468 breast cancer cells.
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Синтез та вивчення протипухлинної активності гідробромідів  
3-R-6-(4-метоксифеніл)-7H-[1,2,4]триазоло[3,4-b][1,3,4]тіадіазину
Мета. Синтезувати та провести вивчення протипухлинної активності 3-R-6-(4-метоксифеніл)-7H-[1,2,4]- 
триазоло[3,4-b][1,3,4]тіадіазинів.
Результати та їх обговорення. Для визначення протипухлинної активності гідробромідів 3-R-6-(4- 
метоксифеніл)-7H-[1,2,4]триазоло[3,4-b][1,3,4]тіадіазинів проведено їх in vitro дослідження на 60 лініях ра-
кових клітин (лейкемії, легень, товстого кишківника, ЦНС, меланоми, яєчників, нирок, простати, молочної 
залози) за стандартною процедурою оцінки мітотичної активності нових потенційних біологічно активних 
сполук методом флуоресцентного фарбування (барвник – сульфородамін Б). Дослідження виконано в Націо- 
нальному інституті раку США (National Cancer Institute, USA) в рамках программи «Development Therapeutic 
Program». З’ясовано, що похідні 3-R-6-(4-метоксифеніл)-7H-[1,2,4]триазоло[3,4-b][1,3,4]тіадіазину про-
являють протипухлинну активність у широкому діапазоні ліній клітин раку і є перспективними базовими 
структурами для створення нових ефективних протипухлинних засобів.
Експериментальна частина. Гідроброміди 3-R-6-(4-метоксифеніл)-7H-[1,2,4]триазоло [3,4-b][1,3,4]- 
тіадіазинів було синтезовано взаємодією 4-аміно-5-R-4Н-1,2,4-триазол-3-тіолів з 4-метоксифенацилбро-
мідом у середовищі етилацетату. 1H ЯМР-спектри було зареєстровано на спектрометрі Bruker VXR-300 
(Німеччина), робоча частота – 299,945 МГц.
Висновки. Синтезовано ряд гідробромідів 3-алкіл-6-(4-метоксифеніл)-7H-[1,2,4]триазоло[3,4-b][1,3,4]- 
тіадіазинів. Вивчено протиракову активність одержаних сполук на 60 лініях пухлинних клітин у Національ- 
ному інституті раку США. Ідентифіковано високоактивні сполуки, які проявили високий рівень проти-
пухлинної активності. Доведено, що введення до базової сполуки етильного або пентильного радикалів   
у положення 3 гетероциклічної системи призводить до підвищення її протипухлинної активності щодо клі-
тин раку молочної залози MDA-MB-468.
Ключові слова: 7Н-[1,2,4]триазоло[3,4-b][1,3,4]тіадіазин; анастрозол; протипухлинна активність
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Cancer is the second most important cause of mor-
tality in the world. Thus, in 2018, 9.6 million people 
died from the disease according to the WHO. About 
one third of deaths from cancer are due to five major 
sources of risk – a high body mass index, low levels 
of fruit and vegetable consumption, the lack of phy- 
sical activity, smoking and excessive alcohol use. Smo- 
king is the most significant risk factor for cancer de-
velopment, accounting for almost 22 % of the world 
deaths from cancer [1]. Up to 25 % of cases of cancer 
in low- and middle-income countries are due to infec-
tions, such as hepatitis and human papillomavirus [2]. 
The prostate and lungs in men and the mammary gland 
in women are the most commonly affected by cancer.
Nowadays, cyclophosphamide, methotrexate, vin-
cristine, adriablastin are widely used to treat tumor 
diseases. These drugs exhibit the necessary healing 
properties, but have significant side effects on the he-
matopoietic system (leukopenia, anemia, thrombocyto-
penia), central nervous system (feeling tired, dizziness, 
headache, aphasia, drowsiness, seizures), reproduc-
tive system (disorder of oogenesis and spermatoge- 
nesis, oligospermia, menstrual irregularity, decreased 
libido, impotence), urinary system (hematuria, cys-
titis, severe renal dysfunction), allergic and derma-
tological reactions, etc. In this way, the search for new 
highly effective antitumor drugs remains a pressing 
issue today.
Previously, triazole derivatives have been pro- 
ven to have the antitumor activity. The known drug 
anastrozole [3 – 7] (a derivative of 1,2,4-triazole) is ac-
tive against estrogen dependent tumors of the breast 
in women. It is a selective non-steroidal enzyme an-
tagonist of aromatase, which leads to a decrease in 
estradiol levels in peripheral tissues. 
It is also known that derivatives of triazole and 
thiadiazine demonstrate a wide range of biological 
effects [8 – 10]. On the other hand, derivatives of 7H- 
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine exhibit the anti-




hydrobromides 3a – g were synthesized by the inter-
action of 4-amino-5-R-4H-1,2,4-triazole-3-thiols 2a – g 
with 4-methoxyphenacyl bromide with relatively high 
yields (Scheme). Starting triazoles 2b – g were obtai- 
ned by the reaction of thiocarbohydrazide (1) with 
the corresponding carboxylic acids, for 5-unsubsti-
tuted triazole 2a formamide was used as a condensing 
reagent.
To determine the antineoplastic activity of 3-R-6- 
(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]- 
thiadiazine hydrobromides 3 the in vitro study was 
conducted on 60 lines of cancer cells (leukemia, non- 
small cell lung cancer, colon cancer, CNS cancer, mela-
noma, ovarian cancer, renal cancer, prostate cancer 
and breast cancer) according to the standard proce-
dure of the mitotic activity assessment of new poten-
tial bioactive compounds by the fluorescent coloring 
method (sulforhodamine B as a dye) performed in 
the US National Cancer Institute within the Develop-
ment Therapeutic Program [14]. The substances were 
used in the concentration of 10-5 mol/L, cancer cells 
were incubated with the compounds for 48 hours. 
The results of the studies conducted were expressed 
as a percentage of the cancer cell growth compared 
to the reference drug 5-fluorouracil (Table 1). In vitro 
experiments revealed high levels of the anti-tumor 
activity of the test compounds against almost all lines 
of cancer cells.
According to the Table 1 compounds 3c – g posses- 
sed higher levels of the antineoplastic activity against 
cells of leukemia, non-small cell lung cancer, colon 
cancer, CNS cancer, melanoma, ovarian cancer, renal 
cancer, prostate cancer and breast cancer compared 
to those of the reference drug 5-fluorouracil. Com-
pounds 3a,b showed the activity at the level of the re- 
ference drug. Compound 3a exceeded the activity of 
the reference drug for 23 lines of cancer cells, 3b – 
for 21 lines, 3c – for 51 lines, 3d – for 52 lines, 3e – 
for 59 lines, 3f – for 54 lines, and 3g – for 57 lines 
among 60 lines studied.
Compounds 3c – g inhibited MDA-MB-435 mela-
noma cells growth at the levels of –13.02 %, –0.35 %, 
–7.41 %, –2.71 % and –12.56 %, respectively, i.e. they 
not only stopped the growth and division of the cells, 
but also killed them.
It should be noted that compound 3c stopped 
the growth and division of MDA-MB-468 cells of breast 
cancer, and destroyed them at the level of –0.91 %. 
Scheme. The synthesis of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromides 3a – g
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Table 1
The anti-tumor activity of 3-alkyl-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 
hydrobromides 3a – g
The lines of cancer cells
Compounds
3a 3b 3c 3d 3e 3f 3g
1 2 3 4 5 6 7 8
Leukemia
CCRF-CEM 90.97 99.20 – 64.82 69.44 12.49 60.77
HL-60(TB) – 85.83 46.93 55.20 27.90 7.13 60.75
K-562 109.18 108.09 20.53 16.06 – 12.75 16.29
MOLT-4 92.82 103.14 50.33 19.89 64.99 – 19.06
RPMI-8226 105.99 110.47 68.67 88.64 99.24 45.35 86.34
SR 85.31 68.03 29.11 24.51 54.91 26.47 28.27
Non-Small Cell Lung Cancer
A549/ATCC 94.22 90.34 49.88 68.67 67.22 30.09 60.62
EKVX 87.61 92.21 78.15 – 74.90 45.54 –
HOP-62 97.65 95.18 42.83 61.26 73.46 34.62 66.67
HOP-92 109.07 – – 64.29 98.87 – 76.47
NCI-H226 95.69 97.84 78.24 77.45 83.71 67.42 90.26
NCI-H23 106.43 110.63 71.33 64.42 81.91 44.23 76.58
NCI-H322M 96.23 99.77 95.89 – 96.55 59.24 96.31
NCI-H460 108.92 111.44 54.88 89.91 89.64 12.91 94.61
NCI-H522 106.91 – 59.15 85.24 –0.85 52.83
Colon Cancer
COLO 205 117.74 111.53 49.96 61.02 91.43 – 81.03
HCC-2998 97.59 109.85 52.77 60.96 61.25 40.60 67.68
HCT-116 106.46 99.30 45.53 65.97 58.07 16.10 73.31
HCT-15 101.36 105.47 45.36 43.19 56.59 22.44 46.34
HT29 107.48 106.46 46.90 54.19 47.70 6.79 69.67
KM12 102.22 101.79 36.02 60.06 57.13 28.76 45.45
SW-620 107.50 108.91 43.64 40.15 32.79 18.25 38.02
CNS Cancer
SF-268 106.01 107.92 49.58 86.47 82.04 51.34 83.63
SF-295 100.52 115.19 64.89 – 76.33 4.79 –
SF-539 104.86 99.21 44.73 65.46 69.09 5.83 65.33
SNB-19 98.77 102.23 51.83 – 82.55 43.59 –
SNB-75 90.66 91.35 – 45.72 66.04 13.16 62.68
U251 95.74 95.61 54.54 68.94 64.69 38.41 58.31
Melanoma
LOX IMVI 99.68 100.99 68.24 59.85 58.72 44.57 65.39
MALME-3M 95.40 100.48 109.02 – 85.34 48.54 91.57
M14 103.00 99.31 46.09 55.11 43.34 –1.10 58.63
MDA-MB-435 97.95 96.25 –13.02 –0.35 –7.41 –2.71 –12.56
SK-MEL-2 128.42 137.89 – 62.81 98.22 – 63.37
SK-MEL-28 102.34 105.53 43.09 81.34 68.56 51.54 86.81
SK-MEL-5 101.46 102.54 27.35 72.16 80.99 –0.14 80.05
UACC-257 103.06 102.85 67.04 98.52 86.31 71.97 83.63
UACC-62 103.32 102.85 50.51 73.46 73.59 46.77 67.24
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Compound 3f demonstrated the activity against NCI-H522 
cells of non-small cell lung cancer at the level of –0.85 %, 
SK-MEL-5 melanoma –0.14 %, OVCAR-3 ovarian can-
cer – (–11.98 %), A498 renal cancer – (–1.24 %) and 
MDA-MB-468 breast cancer –19.00 %.
Compound 3с was effective against K-562 and 
SR leukemia cells (exceeding the activity of 5-fluoro-
uracil by 79.47 and 70.89 %, respectively), HOP-62 
non-small cell lung cancer (exceeding 5-fluorouracil 
by 57.17 %), KM12 colon cancer (exceeding 5-fluo-
rouracil by 63.98 %), SF-26 and SF-539 CNS cancer 
(exceeding 5-fluorouracil by 50.42 and 55.27 %, re-
spectively), SK-MEL-5 melanoma (exceeding 5-fluo-
rouracil by 72.65 %), OVCAR-3 and NCI/ADR-RES ova- 
rian cancer (exceeding 5-fluorouracil by 65.51 and 
79.88 %, respectively), CAKI-1, RFX 393 and TK-10 
renal cancer (exceeding 5-fluorouracil by 64.77, 66.27 
and 61.03 %, respectively), MCF7 breast cancer (exce- 
eding 5-fluorouracil by 84.49 %).
Compound 3d was effective against K-562, MOLT-4 
and SR leukemia cells (exceeding the activity of 5-fluo-
rouracil by 83.94, 90.11 and 75.49 %, respectively), 
HCT-15 and SW-620 colon cancer (exceeding 5-fluo-
rouracil by 56.81 and 59.85 %, respectively), SNB-75 
CNS cancer (exceeding 5-fluorouracil by 54.28 %), 
NCI/ADR-RES ovarian cancer (exceeding 5-fluoroura-
cil by 56.69 %), A498 renal cancer (exceeding 5-fluo-
rouracil by 62.19 %), MDA-MB-468 breast cancer 
(exceeding 5-fluorouracil by 79.49 %).
Compound 3e was effective against HL-60(TB) leu-
kemia cells (exceeding the activity of 5-fluorouracil 
by 72.10 %), SW-620 colon cancer (exceeding 5-fluo-
rouracil by 67.21 %), NCI/ADR-RES ovarian cancer 
(exceeding 5-fluorouracil by 70.36 %), MDA-MB-468 
breast cancer (exceeding 5-fluorouracil by 69.26 %).
Compound 3f was effective against HL-60(TB) leu-
kemia cells (exceeding the activity of 5-fluorouracil 
by 92.87 %), NCI-H460 non-small cell lung cancer 
(exceeding 5-fluorouracil by 87.09 %), HT29 colon can-
cer (exceeding 5-fluorouracil by 93.21 %), SF-295 
and SF-539 CNS cancer (exceeding 5-fluorouracil by 
95.21 and 94.17 %, respectively), NCI/ADR-RES ova- 
rian cancer (exceeding 5-fluorouracil by 97.57 %), 
RFX 393 renal cancer (exceeding 5-fluorouracil by 
Continuation of Table 1
1 2 3 4 5 6 7 8
Ovarian Cancer
IGROV1 101.65 101.41 80.84 – 80.55 42.20 75.32
OVCAR-3 111.32 112.41 34.49 81.27 75.70 –11.98 75.79
OVCAR-4 101.54 103.65 53.96 79.35 84.99 51.27 83.69
OVCAR-5 102.79 110.37 77.87 79.26 92.64 57.03 82.13
OVCAR-8 100.21 89.94 72.12 92.40 88.36 31.72 84.02
NCI/ADR-RES 105.02 106.13 20.12 13.31 29.64 2.43 25.32
SK-OV-3 104.23 109.67 – 67.31 82.61 – 80.28
Renal Cancer
786-0 100.46 97.31 78.02 79.35 86.41 33.60 85.66
A498 87.40 101.18 48.97 37.81 49.40 –1.24 10.40
ACHN 109.65 100.21 58.58 81.69 85.73 45.24 84.80
CAKI-1 89.67 108.33 35.23 59.58 56.48 20.80 61.42
RFX 393 104.05 105.12 33.73 82.19 84.29 1.46 89.26
SN12C 99.15 98.16 78.43 82.49 79.94 41.38 76.07
TK-10 103.75 109.96 38.63 75.90 90.87 29.99 80.05
UO-31 89.43 78.24 69.97 – 78.96 40.01 66.22
Prostate Cancer
PC-3 96.76 95.75 84.33 78.43 78.81 25.82 83.73
DU-145 114.20 114.68 74.30 110.63 92.29 16.17 94.00
Breast Cancer
MCF7 94.63 95.47 15.51 47.09 48.16 22.04 52.95
MDA-MB-231/ATCC 109.69 103.56 55.33 76.52 71.09 44.68 74.19
HS 578T 109.74 106.95 48.03 67.25 78.06 23.99 63.93
BT-549 96.41 103.10 – 69.29 68.19 26.08 73.02
T-47D 99.26 89.91 – 67.02 90.75 – 78.22
MDA-MB-468 102.99 101.90 –0.91 20.51 30.74 –19.00 39.55
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98.54 %), PC-3 and DU-145 prostate cancer (exceeding 
5-fluorouracil by 74.18 and 83.83 %, respectively), MCF7 
breast cancer (exceeding 5-fluorouracil by 77.96 %).
Compound 3g was effective against K-562 and 
MOLT-4 leukemia cells (exceeding the activity of 5-fluo-
rouracil by 83.71 and 80.94 %, respectively), SW-620 
colon cancer (exceeding 5-fluorouracil by 61.98 %), 
NCI/ADR-RES ovarian cancer (exceeding 5-fluoroura-
cil by 74.68 %), A498 renal cancer (exceeding 5-fluoro-
uracil by 89.60 %), MDA-MB-468 breast cancer (exce- 
eding 5-fluorouracil by 60.45 %).
At the second stage of the study the most active 
compounds 3c, 3f and 3g were tested in five concen-
trations in 10-fold dilution series (100 μm, 10 μm, 
1 μm, 0.1 μm and 0.01 μm) on the lines of human can-
cer cells listed above. As a result of the experiment, 
three dose-dependent parameters were calculated: 
the GI50 value (the growth inhibitory activity, effec-
tive inhibition level) corresponded to the concentra-
tion of the compound causing 50 % decrease in the net 
cell growth, the TGI value (cytostatic activity) – the con-
centration of the compound resulting in the total growth 
inhibition (TGI), and the LC50 value (cytotoxic activity) – 
the concentration of the compound causing a net 50 % 
loss of initial cells at the end of the incubation period. 
If logarithmic values of the parameters studied (lgGI50, 
lgTGI and lgLC50) were less than –4.00, the compound 
was considered to be active [14 – 16].
According to the screening results (Table 2), the com- 
pounds demonstrated the considerable level of the anti-
Table 2
The results of the in-depth in vitro screening of compounds 3c,f,g in the concentration  
gradient of 10–4 – 10–8 М
The lines of cancer cells
Compounds
3с 3f 3g
lgGI50 lgTGI lgLC50 lgGI50 lgTGI lgLC50 lgGI50 lgTGI lgLC50
1  2 3 4 5 6 7 8 9 10
Leukemia
CCRF-CEM –5.32 –4.00 –4.00 –5.80 –4.71 –4.00 –5.25 –4.00 –4.00
HL-60(TB) –5.20 –4.19 –4.00 –5.60 –5.10 –4.00 –4.92 –4.00 –4.00
K-562 –5.78 –4.00 –4.00 –5.51 –4.87 –4.00 –6.19 –4.00 –4.00
MOLT-4 –5.22 –4.00 –4.00 –5.56 –4.89 –4.00 –5.42 –4.00 –4.00
RPMI-8226 –4.94 –4.31 –4.00 –5.70 –4.73 –4.00 –4.81 –4.00 –4.00
SR –5.39 –4.00 –4.00 –5.52 –4.99 –4.00 –6.22 –4.00 –4.00
Non-Small Cell Lung Cancer
A549/ATCC –4.90 –4.00 –4.00 –5.73 –4.38 –4.00 –5.26 –4.00 –4.00
EKVX –5.11 –4.00 –4.00 –5.29 –4.36 –4.00 – – –4.00
HOP-62 –5.01 –4.00 –4.00 –6.05 –4.84 –4.33 –4.92 –4.01 –4.00
HOP-92 –5.39 –4.00 –4.00 –5.74 –4.87 –4.25 –6.10 –4.72 –4.00
NCI-H226 –4.49 –4.00 –4.00 –5.36 –4.68 –4.23 –4.20 –4.00 –4.00
NCI-H23 –5.24 –4.00 –4.00 –5.75 –4.52 –4.00 –5.14 –4.00 –4.00
NCI-H322M –4.34 –4.00 –4.00 –5.12 –4.03 –4.00 –4.65 –4.00 –4.00
NCI-H460 –5.14 –4.00 –4.00 –5.58 –4.93 –4.37 –4.97 –4.00 –4.00
NCI-H522 –5.37 –4.22 –4.00 –5.84 –5.08 –4.31 –5.31 –4.32 –4.00
Colon Cancer
COLO 205 –5.01 –4.00 –4.00 –5.89 –5.14 –4.36 –4.92 –4.00 –4.00
HCC-2998 –4.91 –4.26 –4.00 –5.78 –4.95 –4.36 –5.00 –4.00 –4.00
HCT-116 –5.16 –4.00 –4.00 –6.04 –4.90 –4.42 –5.06 –4.00 –4.00
HCT-15 –5.17 –4.00 –4.00 –5.93 –4.66 –4.00 –5.31 –4.00 –4.00
HT29 –5.20 –4.00 –4.00 –6.29 –4.97 –4.31 –5.02 –4.00 –4.00
KM12 –5.26 –4.00 –4.00 –6.02 –4.77 –4.31 –5.31 –4.00 –4.00
SW-620 –5.17 –4.00 –4.00 –6.26 –4.42 –4.00 –5.34 –4.00 –4.00
CNS Cancer
SF-268 –4.84 –4.00 –4.00 –5.26 –4.58 –4.08 –4.92 –4.00 –4.00
SF-295 –5.32 –4.00 –4.00 –6.07 –4.98 –4.43 –5.64 –4.84 –4.00
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carcinogenic activity. Compound 3f showed the sig-
nificant level of the anticarcinogenic activity against 
HOP-62 non-small cell lung cancer (lgGI50 = –6.05; 
lgTGI = –4.84; lgLC50 = –4.33), HOP-92 (lgGI50 = –5.74; 
lgTGI = –4.87; lgLC50 = –4.25), NCI-H226 (lgGI50 = –5.36; 
lgTGI = –5.28; lgLC50 = –4.27), NCI-H460 (lgGI50 = –5.58; 
lgTGI = –4.93; lgLC50 = –4.37), NCI-H522 (lgGI50 = –5.84; 
lgTGI = –5.08; lgLC50 = –4.31); COLO 205 colon can-
cer (lgGI50 = –5.89; lgTGI = –5.14; lgLC50 = –4.36), 
HCC-2998 (lgGI50 = –5.78; lgTGI = –4.95; lgLC50 = –4.36), 
Continuation of Table 2
1  2 3 4 5 6 7 8 9 10
SF-539 –5.32 –4.00 –4.00 –5.83 –5.25 –4.57 –5.36 –4.59 –4.00
SNB-19 –4.87 –4.00 –4.00 –5.65 –4.62 –4.06 –4.85 –4.00 –4.00
SNB-75 –5.33 –4.00 –4.00 –5.74 –5.09 –4.41 –5.37 –4.15 –4.00
U251 –5.11 –4.00 –4.00 –6.01 –4.80 –4.34 –5.10 –4.00 –4.00
Melanoma
LOX IMVI –5.19 –4.00 –4.00 –5.81 –4.74 –4.28 –5.19 –4.00 –4.00
MALME-3M – – – –4.93 –4.52 –4.10 –4.00 –4.00 –4.00
M14 –5.00 –4.00 –4.00 –6.24 –4.84 –4.36 –5.32 –4.00 –4.00
MDA-MB-435 –6.02 –5.37 –4.00 –6.64 –6.09 –4.47 –6.44 –5.77 –5.00
SK-MEL-2 –4.80 –4.00 –4.00 –6.05 –4.72 –4.27 –5.52 –4.46 –4.00
SK-MEL-28 –4.73 –4.00 –4.00 –5.29 –4.66 –4.27 –4.80 –4.00 –4.00
SK-MEL-5 –5.50 –4.73 –4.00 –5.74 –4.94 –4.47 –5.29 –4.00 –4.00
UACC-257 –4.44 –4.00 –4.00 –4.84 –4.47 –4.09 –4.00 –4.00 –4.00
UACC-62 –4.98 –4.00 –4.00 –6.07 –4.78 –4.26 –5.31 –4.00 –4.00
Ovarian Cancer
IGROV1 –4.80 –4.00 –4.00 –5.42 –4.48 –4.00 –5.02 –4.00 –4.00
OVCAR-3 –5.18 –4.00 –4.00 –5.91 –5.44 –4.00 –5.23 –4.51 –4.00
OVCAR-4 –4.45 –4.00 –4.00 –5.29 –4.15 –4.00 –4.46 –4.00 –4.00
OVCAR-5 –4.49 –4.00 –4.00 – – – –4.51 –4.00 –4.00
OVCAR-8 –4.69 –4.00 –4.00 –5.49 –4.63 –4.00 –4.68 –4.00 –4.00
NCI/ADR-RES –5.54 –4.00 –4.00 –6.48 –5.15 –4.00 –5.48 –4.05 –4.00
SK-OV-3 –5.41 –4.35 –4.00 –5.92 –5.07 –4.00 –5.06 –4.00 –4.00
Renal Cancer
786-0 –4.73 –4.00 –4.00 –5.29 –4.69 –4.30 –4.71 –4.00 –4.00
A498 –5.21 –4.00 –4.00 –6.38 –5.22 –4.46 –5.71 –4.28 –4.00
ACHN –4.78 –4.00 –4.00 – – – –4.81 –4.00 –4.00
CAKI-1 –5.34 –4.00 –4.00 –5.92 –4.57 –4.00 –5.16 –4.00 –4.00
RFX 393 –5.53 –4.58 –4.00 –5.84 –5.25 –4.57 –5.66 –4.67 –4.00
SN12C –5.05 –4.00 –4.00 –5.57 –4.69 –4.27 –5.02 –4.00 –4.00
TK-10 –4.68 –4.00 –4.00 –5.40 –4.49 –4.00 –4.81 –4.00 –4.00
UO-31 –5.15 –4.00 –4.00 –5.38 –4.66 –4.20 –5.02 –4.00 –4.00
Prostate Cancer
PC-3 –4.85 –4.00 –4.00 –5.35 –4.46 –4.00 –4.73 –4.00 –4.00
DU-145 –4.77 –4.00 –4.00 –5.39 –4.63 –4.00 –4.91 –4.00 –4.00
Breast Cancer
MCF7 –5.33 –4.00 –4.00 –6.17 –4.74 –4.24 –5.33 –4.00 –4.00
MDA-MB-231/ATCC –4.89 –4.00 –4.00 –6.13 –4.82 –4.27 –4.99 –4.00 –4.00
HS 578T –4.44 –4.00 –4.00 –5.64 –4.43 –4.00 –4.92 –4.00 –4.00
BT-549 –4.71 –4.00 –4.00 –5.22 –4.66 –4.31 –5.07 –4.00 –4.00
T-47D –5.28 –4.00 –4.00 –5.57 –4.54 –4.00 –5.05 –4.00 –4.00
MDA-MB-468 –5.72 –5.05 –4.00 –6.47 –5.40 –4.15 –5.75 –5.09 –4.00
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HCT-116 (lgGI50 = –6.04; lgTGI = –4.90; lgLC50 = –4.42), 
HT29 (lgGI50 = –6.29; lgTGI = –4.97; lgLC50 = –4.31), 
KM12 (lgGI50 = –6.02; lgTGI = –4.77; lgLC50 = –4.31); 
SF-268 CNS cancer (lgGI50 = –5.26; lgTGI = –4.58; 
lgLC50 = –4.08), SF-295 (lgGI50 = –6.07; lgTGI = –4.98; 
lgLC50 = –4.43), SF-539 (lgGI50 = –5.83; lgTGI = –5.25; 
lgLC50 = –4.57), SNB-19 (lgGI50 = –5.65; lgTGI = –4.62; 
lgLC50 = –4.06), SNB-75 (lgGI50 = –5.74; lgTGI = –5.09; 
lgLC50 = –4.41), U251 (lgGI50 = –6.01; lgTGI = –4.80; 
lgLC50 = –4.34); LOX IMVI melanoma (lgGI50 = –5.81; 
lgTGI = –4.74; lgLC50 = –4.28), MALME-3M (lgGI50 = –4.93; 
lgTGI = –4.52; lgLC50 = –4.10), M14 (lgGI50 = –6.24; 
lgTGI = –4.84; lgLC50 = –4.36), MDA-MB-435 (lgGI50 = 
–6.64; lgTGI = –6.09; lgLC50 = –4.47), SK-MEL-2 (lgGI50 = 
–6.05; lgTGI = –4.72; lgLC50 = –4.27), SK-MEL-28 (lgGI50 = 
–5.29; lgTGI = –4.66; lgLC50 = –4.27), SK-MEL-5 (lgGI50 = 
–5.74; lgTGI = –4.94; lgLC50 = –4.47), UACC-257 (lgGI50 = 
–4.84; lgTGI = –4.47; lgLC50 = –4.09), UACC-62 (lgGI50 = 
–6.07; lgTGI = –4.78; lgLC50 = –4.26), 786-0 renal 
cancer (lgGI50 = –5.29; lgTGI = –4.69; lgLC50 = –4.30), 
A498 (lgGI50 = –6.38; lgTGI = –5.22; lgLC50 = –4.46), 
RFX 393 (lgGI50 = –5.84; lgTGI = –5.25; lgLC50 = –4.57), 
SN12C (lgGI50 = –5.57; lgTGI = –4.69; lgLC50 = –4.27), 
UO-31 (lgGI50 = –5.38; lgTGI = –4.66; lgLC50 = –4.20), 
MCF7 breast cancer (lgGI50 = –6.17; lgTGI = –4.74; 
lgLC50 = –4.24), MDA-MB-231/ATCC (lgGI50 = –6.13; 
lgTGI = –4.82; lgLC50 = –4.27), BT-549 (lgGI50 = –5.22; 
lgTGI = –4.66; lgLC50 = –4.31), MDA-MB-468 (lgGI50 = 
–6.47; lgTGI = –5.40; lgLC50 = –4.15).
Compound 3g had the anticarcinogenic activity 
against MDA-MB-435 melanoma (lgGI50 = –6.44; lgTGI = 
–5.77; lgLC50 = –5.00).
Thus, derivatives of 3-R-6-(4-methoxyphenyl)- 
7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine exhibit the anti-
neoplastic activity against a wide range of cancer cells 




4-Amino-5-R-4H-1,2,4-triazole-3-thiols 2b – g were 
synthesized according to the method described in [18], 
4-amino-4H-1,2,4-triazole-3-thiol (2a) was synthesized 
by the method [19].
1Н NMR spectra were recorded on a Bruker VXR-
300 (Germany), the working frequency – 299.945 MHz, 
in DMSO-d6 using TMS as an internal standard. Chemi-
cal shifts were reported in ppm units using the δ scale.
The melting points were measured on a small-
sized heating table with a RNMK 05 observation de-
vice (VEB Analytik, Dresden).
The general procedure for the synthesis of 
3-R-6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b]- 
[1,3,4]thiadiazines 3a – g. The mixture of the appro-
priate 4-amino-4H-1,2,4-triazole-3-thiol 2a – g (0.01 mol) 
and 4-methoxyphenacyl bromide (2.29 g; 0.01 mol) 
was refluxed in 50 mL of ethyl acetate during 2 hours. 
After cooling the precipitate of salts 3a – g was filte- 
red off, washed with ethyl acetate, dried on air and 
recrystallized from ethanol.
6-(4-Methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b]
[1,3,4]thiadiazine hydrobromide (3a). Yield – 2.59 g 
(79 %). M. p. 142 – 144 °C (from ethanol). Anal. Calcd. for 
С11H11BrN4OS, %: N 17.12. Found, %: N 17.01. 1H NMR 
(300 MHz, DMSO-d6), δ, ppm: 3.86 (3H, s, ОCH3); 4.41 
(2H, s, SCH2); 7.12 and 7.97 (2Н, d, J = 8.7 Hz, С6Н4); 
9.12 (1H, s, 3-CH).
6-(4-Methoxyphenyl)-3-methyl-7H-[1,2,4]- 
triazolo[3,4-b][1,3,4]thiadiazine hydrobromide (3b). 
Yield – 2.76 g (81 %). M. p. 205 – 207 °C (from ethanol). 
Anal. Calcd. for С12H13BrN4OS, %: N 16.42. Found, %: 
N 16.60. 1H NMR (300 MHz, DMSO-d6), δ, ppm: 2.60 
(3H, s, CH3); 3.87 (3H, s, ОCH3); 4.45 (2H, s, SCH2); 
7.14 and 8.05 (2Н, d, J = 8.7 Hz, С6Н4).
3-Ethyl-6-(4-methoxyphenyl)-7H-[1,2,4]tria- 
zolo[3,4-b][1,3,4]thiadiazine hydrobromide (3c). 
Yield – 2.94 g (83 %). M. p. 236 – 238 °C (from ethanol). 
Anal. Calcd. for С13H15BrN4OS, %: N 15.77. Found, %: 
N 15.72. 1H NMR (300 MHz, DMSO-d6), δ, ppm: 1.33 
(3H, t, J = 7.6 Hz, CH3); 3.00 (2H, q, J = 7.6 Hz, CH2); 
3.87 (3H, s, ОCH3); 4.46 (2H, s, SCH2); 7.15 and 8.04 
(2Н, d, J = 9.0 Hz, С6Н4).
6-(4-Methoxyphenyl)-3-propyl-7H-[1,2,4]- 
triazolo[3,4-b][1,3,4]thiadiazine hydrobromide (3d). 
Yield – 2.91 g (79 %). M. p. 212 – 214 °C (from ethanol). 
Anal. Calcd. for С14H17BrN4OS, %: N 15.17. Found, %: 
N 15.10. 1H NMR (300 MHz, DMSO-d6), δ, ppm: 1.06 
(3H, t, J = 7.6 Hz, CH3); 1.81 – 1.91 (2H, m, CH2); 3.01 
(2H, t, J = 8.0 Hz, CH2); 3.87 (3H, s, ОCH3); 4.46 (2H, s, 
SCH2); 7.06 and 8.04 (2Н, d, J = 8.8 Hz, С6Н4).
6-(4-Methoxyphenyl)-3-butyl-7H-[1,2,4]tria- 
zolo[3,4-b][1,3,4]thiadiazine hydrobromide (3e). 
Yield – 2.99 g (78 %). M. p. 193 – 195 °C (from ethanol). 
Anal. Calcd. for С15H19BrN4OS, %: N 14.62. Found, %: 
N 14.83. 1H NMR (300 MHz, DMSO-d6), δ, ppm: 0.94 
(3H, t, J = 7.6 Hz, CH3); 1.35 – 1.44 (2H, m, CH2); 1.69 – 1.77 
(2H, m, CH2); 2.92 (2H, t, J = 8.0 Hz, CH2); 3.86 (3H, 
s, ОCH3); 4.36 (2H, s, SCH2); 7.08 and 7.92 (2Н, d, 
J = 8.8 Hz, С6Н4).
6-(4-Methoxyphenyl)-3-pentyl-7H-[1,2,4]- 
triazolo[3,4-b][1,3,4]thiadiazine hydrobromide (3f). 
Yield – 2.70 g (68 %). M. p. 185 – 187 °C (from ethanol). 
Anal. Calcd. for С16H21BrN4OS, %: N 14.10. Found, %: 
N 14.03. 1H NMR (300 MHz, DMSO-d6), δ, ppm: 0.94 
(3H, t, J = 7.6 Hz, CH3); 1.34 – 1.45 (4H, m, 2 × CH2); 
1.75 – 1.83 (2H, m, CH2); 2.94 (2H, t, J = 8.0 Hz, CH2); 
3.89 (3H, s, ОCH3); 4.32 (2H, s, SCH2); 7.03 and 7.98 
(2Н, d, J = 8.8 Hz, С6Н4).
6-(4-Methoxyphenyl)-3-(trifluoromethyl)-7H- 
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine hydrobromide (3g). 
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Yield – 2.84 g (72 %). M. p. 162 – 164 °C (from eth-
anol). Anal. Calcd. for С12H10BrF3N4OS, %: N 14.18. 
Found, %: N 14.45. 1H NMR (300 MHz, DMSO-d6), δ, ppm: 
3.88 (3H, s, ОCH3); 4.48 (2H, s, SCH2); 7.11 and 7.98 
(2Н, d, J = 9.0 Hz, С6Н4). 
Biology Part
The methodology of the NCI procedure for the pri-
mary anticancer assay is detailed in Anticancer Drug 
Development Guide [14]. Briefly, the protocol was per-
formed on 60 human tumor cell lines derived from 
different nine neoplastic diseases. NCI-60 testing was 
performed as a single concentration, which was tested 
on all 60 cell lines in a single dose of 10−5 M. All of the as-
says were in accordance with the protocol of the Drug 
Evaluation Branch, National Cancer Institute, Bethesda, 
USA. If the results obtained met selection criteria, then 
the compound was tested again on all 60 cell lines in 
5 × 10-fold dilutions with the top dose being 10−4 M.
Conclusions
1. A series of 3-R-6-(4-methoxyphenyl)-7H-[1,2,4]- 
triazolo[3,4-b][1,3,4]thiadiazines has been synthesized 
by the interaction of 4-amino-5-R-4H-1,2,4-triazole-
3-thiols with 4-methoxyphenacyl bromide in ethyl ace-
tate. The structure and purity of all the products have 
been confirmed by 1H NMR spectroscopy and elemen- 
tal analysis.
2. Derivatives of 3-R-6-(4-methoxyphenyl)-7H- 
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine have been pro- 
ven to have the high level of the antitumor activity 
against leukemia, non-small cell lung cancer, colon 
cancer, CNS cancer, melanoma, ovarian cancer, renal 
cancer, prostate cancer and breast cancer, and thus, 
can be recommended for in-depth preclinical studies.
Conflict of interests: the authors have no con-
flict of interests to declare.
References
1. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer (accessed Apr 10, 2020).
2. Plummer, M.; de Martel, C.; Vignat, J.; Ferlay, J.; Bray, F.; Franceschi, S. Global burden of cancers attributable to infections in 2012: a synthetic 
analysis. Lancet Glob. Health 2016, 4 (9), e609 – e616. https://doi.org/10.1016/S2214-109X(16)30143-7.
3. Ogasa, Y.; Kuwamura, T.; Akiyoshi, T.; Murakami, S.; Tanaka, H.; Umeda, S.; Suematsu F. Evaluation of patient adherence to anastrozole therapy for 
breast cancer. Gan To Kagaku Ryoho 2018, 45 (6), 965 – 968.
4. Barros-Oliveira, M. d. C.; Costa-Silva, D. R.; Andrade, D. B. d.; Borges, U. S.; Tavares, C. B.; Borges, R. S.; Silva, J. d. M.; Silva, B. B. d. Use of anastrozole 
in the chemoprevention and treatment of breast cancer: A literature review. Revista da Associação Médica Brasileira 2017, 63, 371 – 378. http://
dx.doi.org/10.1590/1806-9282.63.04.371.
5. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone 
for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer 2003, 98 (9), 1802 – 1810. https://doi.org/10.1002/
cncr.11745.
6. Kravchenko, T. V.; Panasenko, O. I.; Knysh, E. G. Biological activity of the derivatives of 1,2,4-triazole. Farmatsevtychnyi zhurnal 2018, 5, 25 – 30. 
https://doi.org/10.32352/0367-3057.5.16.02.
7. The BIG 1-98 Collaborative Group. Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. N. Engl. J. Med. 2009, 
361 (8), 766 – 776. https://doi.org/10.1056/NEJMoa0810818.
8. Aggarwal, N.; Kumar, R.; Dureja, P.; Khurana, J. M. Synthesis, antimicrobial evaluation and QSAR analysis of novel nalidixic acid based 1,2,4-tria-
zole derivatives. Eur. J. Med. Chem. 2011, 46 (9), 4089 – 4099. https://doi.org/10.1016/j.ejmech.2011.06.009.
9. Kumar, D.; Narayanam, M. K.; Chang, K.-H.; Shah, K. Synthesis of Novel Indolyl-1,2,4-triazoles as Potent and Selective Anticancer Agents. Chemical 
Biology & Drug Design 2011, 77 (3), 182 – 188. https://doi.org/10.1111/j.1747-0285.2010.01051.x.
10. Khan, I.; Zaib, S.; Ibrar, A.; Rama, N. H.; Simpson, J.; Iqbal, J. Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-
1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines. Eur. J. Med. Chem. 2014, 78, 167 – 177. https://doi.org/10.1016/j.ejmech.2014.03.046.
11. Purohit, D. H.; Dodiya, B. L.; Ghetiya, R. M.; Vekariya, P. B.; Joshi H. S. Synthesis and antimicrobial activity of some new 1,3,4-thiadiazoles and 
1,3,4-thiadiazines containing 1,2,4-triazolo nucleus. Acta Chim. Slov. 2011, 58, 53 – 59.
12. Prakash, O.; Aneja, D. K.; Hussain, K.; Lohan, P.;  Ranjan, P.; Arora, S.; Sharma, C.; Aneja, K. R. Synthesis and biological evaluation of dihydroindeno 
and indeno[1,2-e][1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as antimicrobial agents. Eur. J. Med. Chem. 2011, 46 (10), 5065 – 5073. https://doi.
org/10.1016/j.ejmech.2011.08.019.
13. El Shehry, M. F.; Abu-Hashem, A. A.; El-Telbani, E. M. Synthesis of 3-((2,4-dichlorophenoxy)methyl)-1,2,4-triazolo(thiadiazoles and thiadiazines) 
as anti-inflammatory and molluscicidal agents. Eur. J. Med. Chem. 2010, 45 (5), 1906 – 1911. https://doi.org/10.1016/j.ejmech.2010.01.030.
14. Teicher, B. A.; Andrews, P. A., Eds. Anticancer Drug Development Guide; Humana Press: 2004.
15. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility 
of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. Cancer Res. 1988, 48 (3), 589 – 601.
16. Carter, P. H.; Scherle, P. A.; Muckelbauer, J. A.; Voss, M. E.; Liu, R.-Q.; Thompson, L. A.; Tebben, A. J.; Solomon, K. A.; Lo, Y. C.; Li, Z.; Strzemienski, 
P.; Yang, G.; Falahatpisheh, N.; Xu, M.; Wu, Z.; Farrow, N. A.; Ramnarayan, K.; Wang, J.; Rideout, D.; Yalamoori, V.; Domaille, P.; Underwood, D. J.; 
Trzaskos, J. M.; Friedman, S. M.; Newton, R. C.; Decicco, C. P. Photochemically enhanced binding of small molecules to the tumor necrosis factor 
receptor-1 inhibits the binding of TNF-α. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (21), 11879 – 11884. https://doi.org/10.1073/pnas.211178398.
17. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 1992, 
19 (6), 622 – 638.
18. Hou, N.; Xu, L. J. Synthesis and bacteriostatic activity of new thiosemicarbazone derivatives – aminomercaptotriazole Schiff bases. Yaoxue Xuebao 
1992, 27 (10), 738 – 742.
19. 5-(β-hydroxyethylthio)-4-amino-1,2,4-(4H)-triazol. In Sintezy geterotsiklicheskikh soyedineniy; Mndzhoyan, A. L., Ed.; Academy of Sciences of 
Armenian SSR: Yerevan, 1964; Vol. 6, pp. 41 – 43.
Received: 04. 02. 2020 
Revised:  03. 09. 2020 
Accepted:  17. 09. 2020
The work was carried out according to the research plan of the Nizhyn Mykola Gogol State University on the topic  
“Synthesis of novel sulphur and nitrogen containing heterocyclic compounds and investigation of their practically useful properties’’  
(the state registration No. 0115U005451; the research period: 2015 – 2019).
